Bharat Seats Approves FY26 Results, Recommends 75% Dividend, & Rs. 86.61 Cr Capex
Bharat Seats Limited approved its audited financial results for FY26 and Q4FY26. The company recommended a 75% dividend (₹1.50 per share) with a record date of July 17, 2026. A capital expenditure of ₹86.61 crore was approved for new Maruti Suzuki programs. The 39th AGM is scheduled for July 24, 2026. Mr. Rishabh Relan's re-appointment as Whole-time Director was recommended.
The announcement includes approval of financial results, a dividend recommendation, a substantial capital expenditure plan, and a key management re-appointment, all of which are material to investors and the company's operations.
The company reported its annual and quarterly results, recommended a dividend, approved significant capital expenditure, and recommended the re-appointment of a director, all of which are positive indicators for stakeholders.
Bharat Seats Limited announced the outcome of its Board of Directors meeting held on May 6, 2026. The Board considered and approved the Annual Financial Statements and the Audited Financial Results for the quarter and financial year ended March 31, 2026. The company also took note of the unmodified Auditors' Report from S.R. Batliboi & Co., LLP.
The company approved a capital expenditure of approximately ₹86.61 crores for new programs of Maruti Suzuki India Limited, to be implemented at its Kharkhoda and Gujarat Navyani plants. This expenditure is in the ordinary course of business.
Furthermore, the Board approved the Draft Notice of the 39th Annual General Meeting (AGM), scheduled to be held on Friday, July 24, 2026. They also approved the Draft Directors’ Report, Management Discussion and Analysis, and Corporate Governance Report for the year ended March 31, 2026.
In line with SEBI regulations, the Board recommended a dividend of 75%, which translates to ₹1.50 per equity share of ₹2 each, for the year ended March 31, 2026. The record date for this dividend is July 17, 2026. The dividend, subject to shareholder approval, will be paid within 30 days of declaration.
The Board also considered and approved the revised CSR Policy. Additionally, the Board recommended the re-appointment of Mr. Rishabh Relan as Whole-time Director for another term of three years, from February 4, 2027, to February 3, 2030, subject to shareholder approval. Mr. Relan, son of Chairman & Managing Director Mr. Rohit Relan, has been associated with the company since August 2012 and has experience in the automobile industry.
What to do with a filing like this
Bharat Seats Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bharat Seats Limited. Read the original for the full detail.